Clinical Trials Logo

Infection clinical trials

View clinical trials related to Infection.

Filter by:

NCT ID: NCT00530400 Completed - Clinical trials for Surgical Wound Infection

Study of the Efficacy of Preoperative Cefuroxime Prophylaxis to Prevent Surgical Site Infection in Herniated Disk Surgery

Start date: April 1994
Phase: Phase 4
Study type: Interventional

The purpose of the study is to determine whether a single, pre-operative dose of cefuroxime is effective in preventing surgical site infection in patients undergoing surgery for herniated disk

NCT ID: NCT00529282 Terminated - Fever Clinical Trials

A Study of Ceftobiprole in Patients With Fever and Neutropenia.

Start date: October 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of ceftobiprole versus a comparator in patients with fever and neutropenia

NCT ID: NCT00528476 Completed - Clinical trials for Urinary Tract Infection

Risk Factors for Recurrent Urinary Tract Infection in Children

Start date: November 2004
Phase: N/A
Study type: Observational

The purpose of this study is to determine clinical and urodynamic risk factors for recurrent urinary tract infection in 5-18 years old children.

NCT ID: NCT00528008 Terminated - Wound Infection Clinical Trials

A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections

Start date: December 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to find out if chlorhexidine gluconate solution is better at reducing the rate of wound infection after cesarean section compared to povidone-iodine.

NCT ID: NCT00527878 Terminated - Immune Deficiency Clinical Trials

Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome

Start date: September 2007
Phase: Phase 2
Study type: Interventional

This study will examine the safety and effectiveness of ranitidine (Zantac) in patients with Hyper-IgE recurrent infection syndrome, a disease characterized by recurrent infections of the ears, sinuses, lungs and skin, and abnormal levels of the antibody immunoglobulin E (IgE). Patients age 2 and older who have Hyper-IgE recurrent infection syndrome and who have had chronic or frequent infections in the last 12 months may be eligible for this study. Participants are randomly assigned to take ranitidine or placebo in pill or liquid form twice a day for 12 months. In addition to treatment, patients undergo the following procedures during visits scheduled on day 0 of the study (baseline) and at 3, 12, 15 and 24 months. Evaluations at 6, 9, 18 and 21 months are by telephone. - Medical history and physical examination - baseline and 3 and 24 months. - Clinical severity score - baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months. - Dermatology exam - baseline and 3, 12, 15 and 24 months. - Pulmonary function test - baseline and 12 and 24 months. - Chest CT - baseline and 12 and 24 months. - Quality of life assessment - baseline and 3, 12, 15 and 24 months. - Pregnancy testing - baseline and 3, 12, 15 and 24 months. - HIV test - baseline and 12 and 24 months. - Contraception evaluation - baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months. - Missed school/work days assessment - baseline and 3, 12, 15 and 24 months. - Medication adherence - baseline and 3, 6, 9, 12, 15, 18, 21 and 24 months. In addition to the above procedures, participants who are not enrolled in study 00-I-0159 have a baseline scoliosis series and genetic consult.

NCT ID: NCT00524290 Completed - Clinical trials for Acinetobacter Infections

Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol

Start date: April 2009
Phase:
Study type: Observational

The objectives of this multinational study are to assess the clinical outcomes of patients with Acinetobacter bloodstream infection and to further assess the predictors of mortality in this patient population. We also aim to characterize the molecular epidemiology of this remarkable organism in an attempt to further understand its transmission dynamics on a global level and to determine whether increased pathogenicity is geographically dependent.

NCT ID: NCT00524108 Completed - Infection Clinical Trials

Retrospective Analysis of Clinical Features in Ventriculoperitoneal Shunt Infectionsin Adults

Start date: August 2007
Phase: N/A
Study type: Observational

The objectives of this study are: - To describe the incidence of clinical features in adults with internal ventriculoperitoneal (VP) shunt infections, - To determine the validity of laboratory parameters in adults with internal ventriculoperitoneal shunt infections and - To evaluate the relationship between the timing of shunt re-implantation with the rates of relapse and secondary infection.

NCT ID: NCT00520897 Completed - HIV Infections Clinical Trials

Integrase Inhibitor (MK-0518) Viral Decay

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The eradication of HIV by antiretroviral therapy has thus far been elusive. It has been consistently demonstrated that a pool of latently infected, resting CD4+ T cells persists in the majority of HIV-infected individuals receiving antiretroviral therapy in whom plasma viremia has been successfully suppressed for prolonged periods of time; this pool has emerged as the major obstacle in achieving the eradication of HIV. We believe that MK-0518 can further the decay and suppression of HIV-1 in patients who have been virologically suppressed for a prolonged period of time on effective cART (≥ 4 years).

NCT ID: NCT00518661 Completed - Infection Clinical Trials

Risk Factors for Quinolone Resistance Among ESBL Producing Klebsiella Species

Start date: August 2007
Phase:
Study type: Observational

This is a retrospective chart review. This proposed study aims to document the risk factors for quinolone resistance in bloodstream isolates of Klebsiella species. Additionally, the adequacy of empiric antibiotic therapy for Klebsiella bloodstream infections will be assessed.

NCT ID: NCT00515229 Completed - Cystic Fibrosis Clinical Trials

Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo

Start date: October 2006
Phase: Phase 2
Study type: Interventional

Our data indicate that the CFTR-molecule functions as a transporter for sphingosine-1-phosphate and sphingosine or regulates the uptake of these sphingolipids by epithelial cells. The disturbed uptake of sphingosine and sphingosine-1-phosphate over the cell membrane results in an accumulation of ceramide in the cell membrane, which finally triggers a pro-inflammatory and pro-apoptotic status in the respiratory tract of cystic fibrosis patients. Amitriptyline reduces the cera-mide levels in the lung tissue, normalises the activity of cytokines and prevents constitutive cell death of epithelial cells observed in CFTR-deficient mice. Most important, amitriptyline prevents pulmonary infections of CFTR-deficient mice with P. aeruginosa. These effects of amitriptyline may result in an improved lung function of cystic fibrosis patients.